DOI: 10.7504/nk2014050502
Dose-reduced decitabine treatment of myelodysplastic syndrome-refractory cytopenia with unilineage dysplasia in transfusion dependent patients
Abstract：Objective To evaluate the efficacy and safety of dose-reduced decitabine treatment for transfusion dependent patients with myelodysplastic syndrome-refractory cytopenia with unilineage dysplasia (MDS-RCUD).Methods From November 2009 to May 2012,collect the clinical information of 8 cases of MDS-RCUD,treated by dose-reduced decitabine (20 mg/m2 intravenously once daily for 3 days),and evaluate the efficacy and side-effects of therapy in these patients.Results Of all 8 patients,1 case (12.5％) achieved complete remission (CR),2 cases (25.0％) achieved transfusion independence,3 cases (37.5％) achieved hematologic improvement (HI) and the overall response rate (ORR) was 75.0％.Of the 4 cases in whom cytogenetic evaluation could be performed,1 case (25.0％) achieved partial cytogenetic remission.Grade Ⅳ hematologic toxicity rate was 50.0％,and grade Ⅲ-Ⅳ infection rate was 37.5％.No grade Ⅲ-Ⅳ bleeding,severe nausea and vomiting (Ⅲ-Ⅳ grade),liver injury (Ⅲ-Ⅳ) occurred.The median follow-up time was 386.6 days (108-655 days).At the end of following-up,no patients were dead.Conclusion Dose-reduced treatment of decitabine can reduce transfusion dependence in MDS-RCUD patients with low rates of severe hematologic toxicity and early mortality.
Keywords：myelodysplastic syndromerefractory cytopenia with unilineage dysplasiadecitabinehematologic toxicitydose-reduced
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)